Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323346 | 1.00 | CA1 (0.42) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2306678 | 0.74 | VCP (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1122421 | 0.74 | VCP (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1122423 | 0.74 | VCP (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1324203 | 0.72 | VCP (0.38) | CA1CA2VCPKMT2A | |
| SCHEMBL1324942 | 0.72 | VCP (0.38) | CA1CA2VCPKMT2A | |
| SCHEMBL13790239 | 0.69 | VCP (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL13790319 | 0.69 | VCP (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL8594457 | 0.69 | VCP (0.48) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1323495 | 0.67 | KMT2A (0.47) | CA1CA2CA12CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058313-B2 | 4-((1E)-2-(((E)-2-fluoro-4-cyanostyrylsulfonyl)methylsulfonyl)vinyl)-3-fluoro-benzonitrile; mitogen activated protein kinase inhibitor; cell growth factor receptor antagonist; angiogenesis inhibitor, antiproliferative and anticarcinogenic agent; neurodegenerative diseases | Temple University—Of the Commonwealth System of Higher Education (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-20 | — | — | US | disclosed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070974-A1 | Alpha, Beta-Unsaturated Sulfones, Sulfoxides, Sulfonimides, Sulfinimides, Acylsulfonamides and Acylsulfinamides and Therapeutic Uses Thereof | DEGS1, SULT1E1, PTDSS1 | CA1 1789/4885CA2 4264/4885CA12 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.